Veru Reports Fiscal 2019 Full-Year Net Revenues Doubled, Gross Profit Up 147%
Veru Inc. (VERU)
Last veru inc. earnings: 2/12 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
verupharma.com/investors
Company Research
Source: GlobeNewswire
--Update on Ongoing Phase 1b/2 VERU-111, Oral Selective Antitubulin, Clinical Trial Demonstrates Antitumor Activity and No Dose Related Toxicity Reached in Men with Metastatic Castration Resistant Prostate Cancer-- --VERU-111 Has Promising Signs of Progression Free Survival-- --Advancing VERU-111 into Three Phase 2 Clinical Studies in Additional Cancer Types-- --Company to Host Investor Conference Call Today at 8 a.m. ET to Discuss Financial Results and Clinical Study Data-- MIAMI, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), The Prostate Cancer Company, an oncology and urology biopharmaceutical company developing novel medicines for the management of prostate cancer, today announced that its fiscal 2019 full-year net revenues doubled to $31.8 million and gross profit increased 147% to $21.7 million. “For both the fiscal 2019 fourth quarter and full year, we continue to generate impressive increases to net revenues and gross profit compared wi
Show less
Read more
Impact Snapshot
Event Time:
VERU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VERU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VERU alerts
High impacting Veru Inc. news events
Weekly update
A roundup of the hottest topics
VERU
News
- Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11 [Yahoo! Finance]Yahoo! Finance
- Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11GlobeNewswire
- What Makes Veru (VERU) a New Buy Stock [Yahoo! Finance]Yahoo! Finance
- Veru Inc. (NASDAQ: VERU) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $5.00 price target on the stock, down previously from $7.00.MarketBeat
- Veru Announces Date of 2024 Annual Meeting of Shareholders [Yahoo! Finance]Yahoo! Finance
VERU
Earnings
- 8/10/23 - Beat
VERU
Sec Filings
- 4/25/24 - Form 8-K
- 4/24/24 - Form SC
- 4/1/24 - Form DEFA14A
- VERU's page on the SEC website